

PRESS RELEASE



CONTACTS:

InVasc Therapeutics, Inc.
William D. Johnston, Ph.D.
Chief Executive Officer
(678) 736-5903
bjohnston@invasctherapeutics.com

Nadya Merchant, Ph.D.
Director of Investor Relationships
(678) 736-5907
nmerchant@invasctherapeutics.com

FOR IMMEDIATE RELEASE

INVASC THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE 2010 AND ANNOUNCES DOMAIN NAME CHANGE

ATLANTA, Georgia – January 11, 2010 – InVasc Therapeutics, Inc. today announced that William D. Johnston, Ph.D., Chief Executive Officer, will present an overview of the Company and its pipeline of products for the treatment and prevention of cardiometabolic diseases at the Biotech Showcase 2010 meeting at the Marine Memorial Club and Hotel in San Francisco on Wednesday January 14, 2010 at 4:40 P.M., Pacific Standard Time.

Additionally, InVasc announced it has changed its domain name to www.invasctherapeutics.com and launched its new website. As a result, the Company's new website may now be viewed at this new domain address, and all Company email addresses have been changed to utilize invasctherapeutics.com. All inquiries and emails to the former website will automatically be re-directed to this new domain address.

About InVasc

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a biopharmaceutical company developing drugs to mitigate risks along the cardiometabolic disease continuum. Cardiovascular and metabolic diseases such as diabetes, hypertension and dyslipidemia are the leading causes of morbidity and mortality worldwide. The Company plans to file an IND for INV-142 for the reduction of proteinuria in hypertensive diabetic patients in the first half of 2010. In a human clinical trial, INV-141, a sister compound, demonstrated statistical significance in the reduction of proteinuria in the same patient population. The Company is also advancing two compounds through safety and efficacy studies for atherosclerosis and anticipates entering the clinic with one of these compounds in 2011.

###